Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CRL
stocks logo

CRL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
987.05M
-1.55%
2.345
-11.86%
998.79M
+1.49%
2.559
+9.37%
1.03B
-0.25%
2.839
-9.01%
Estimates Revision
The market is revising Upward the revenue expectations for Charles River Laboratories International, Inc. (CRL) for FY2025, with the revenue forecasts being adjusted by 0.55% over the past three months. During the same period, the stock price has changed by 12.23%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.55%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.69%
In Past 3 Month
Stock Price
Go Up
up Image
+12.23%
In Past 3 Month
Wall Street analysts forecast CRL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRL is 192.73 USD with a low forecast of 165.00 USD and a high forecast of 225.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast CRL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRL is 192.73 USD with a low forecast of 165.00 USD and a high forecast of 225.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 184.040
sliders
Low
165.00
Averages
192.73
High
225.00
Current: 184.040
sliders
Low
165.00
Averages
192.73
High
225.00
Argus
Hold
to
Buy
upgrade
$200
2025-11-17
Reason
Argus
Price Target
$200
2025-11-17
upgrade
Hold
to
Buy
Reason
Argus upgraded Charles River to Buy from Hold with a $200 price target.
Morgan Stanley
Equal Weight
maintain
$170 -> $185
2025-11-11
Reason
Morgan Stanley
Price Target
$170 -> $185
2025-11-11
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Charles River to $185 from $170 and keeps an Equal Weight rating on the shares.
TD Cowen
Charles Rhyee
Buy
downgrade
$205 -> $197
2025-11-10
Reason
TD Cowen
Charles Rhyee
Price Target
$205 -> $197
2025-11-10
downgrade
Buy
Reason
TD Cowen analyst Charles Rhyee lowered the firm's price target on Charles River to $197 from $205 and keeps a Buy rating on the shares. The firm said the company's strategic review update suggests a full Mfr. sale is unlikely, and the reality is DSA revenue growth will be challenged in 2026, with the base case being revenue growth down.
JPMorgan
Neutral
maintain
$160 -> $165
2025-11-06
Reason
JPMorgan
Price Target
$160 -> $165
2025-11-06
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Charles River to $165 from $160 and keeps a Neutral rating on the shares following the Q3 report.
Baird
Eric Coldwell
Neutral -> Outperform
upgrade
$178 -> $199
2025-11-06
Reason
Baird
Eric Coldwell
Price Target
$178 -> $199
2025-11-06
upgrade
Neutral -> Outperform
Reason
Baird analyst Eric Coldwell upgraded Charles River to Outperform from Neutral with a price target of $199, up from $178.
Mizuho
Ann Hynes
Neutral
maintain
$155 -> $174
2025-10-17
Reason
Mizuho
Ann Hynes
Price Target
$155 -> $174
2025-10-17
maintain
Neutral
Reason
Mizuho analyst Ann Hynes raised the firm's price target on Charles River to $174 from $155 and keeps a Neutral rating on the shares as part of a Q3 earnings preview for the healthcare facilities and managed care group. Healthcare utilization growth trends decelerated sequentially in Q3 despite easier year-over-year compares, which could indicate stabilizing cost trends, a positive for managed care companies, the analyst tells investors in a research note. The firm expects solid results from hospitals despite admissions trends falling sequentially. It is also "cautiously optimistic" that contract research organization trends have bottomed.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Charles River Laboratories International Inc (CRL.N) is 17.51, compared to its 5-year average forward P/E of 22.54. For a more detailed relative valuation and DCF analysis to assess Charles River Laboratories International Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
22.54
Current PE
17.51
Overvalued PE
29.24
Undervalued PE
15.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
15.07
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
19.08
Undervalued EV/EBITDA
11.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.08
Current PS
0.00
Overvalued PS
4.13
Undervalued PS
2.02
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areBuying! The buying amount has increased100%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CRL News & Events

Events Timeline

(ET)
2025-12-03
10:00:00
Microchip Stock Rises 4.44% to $61.15
select
2025-11-17 (ET)
2025-11-17
08:10:39
Charles River: SEC Wraps Up Investigation, No Enforcement Action Recommended
select
2025-11-05 (ET)
2025-11-05
09:13:09
Charles River Offers Update on Strategic Assessment
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-04SeekingAlpha
CROs Decline as FDA Chief Makary Indicates Fewer Trials Needed for Drug Approvals

  • FDA Announcement Impact: FDA Commissioner Marty Makary stated that pharmaceutical companies will only need to submit results from one pivotal trial for most new drug approvals, which has negatively affected contract research organizations (CROs) like Charles River Laboratories, ICON, and IQVIA.

  • Market Reaction: Following the announcement, Medpace experienced the largest decline among CROs, dropping approximately 4%, while IQVIA and Fortrea saw a decrease of around 2%.

[object Object]
Preview
1.0
11-17Newsfilter
Charles River Laboratories to Speak at Jefferies Global Healthcare Conference

  • Presentation Announcement: Charles River Laboratories will present at the Jefferies Global Healthcare Conference in London on November 18th at 11:30 a.m. GMT, discussing their strategic focus and recent business developments.

  • Webcast Availability: A live webcast of the presentation will be accessible on the Charles River Investor Relations website, with a replay available for at least two weeks post-event.

  • Company Overview: Charles River Laboratories provides essential products and services to pharmaceutical and biotechnology companies, aiding in research and drug development.

  • Contact Information: For investor relations inquiries, Todd Spencer, Corporate Vice President, can be contacted at 781.222.6455 or via email at todd.spencer@crl.com.

[object Object]
Preview
7.0
11-08PRnewswire
Charles River Laboratories Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL

  • Investigation Announcement: Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., has initiated an investigation into Charles River Laboratories following a subpoena from the U.S. Department of Justice regarding illegal importation of non-human primates for research.

  • Impact on Earnings: The investigation comes after Charles River disclosed that it suspended shipments of primates from Cambodia, which is expected to negatively affect its earnings and revenue growth.

  • Securities Class Action: The company and its executives are facing a securities class action lawsuit for allegedly failing to disclose material information, which is still ongoing.

  • Call for Information: KSF is seeking information from individuals who may assist in the investigation or long-term shareholders of Charles River to discuss their legal rights.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Charles River Laboratories International Inc (CRL) stock price today?

The current price of CRL is 184.04 USD — it has decreased -0.34 % in the last trading day.

arrow icon

What is Charles River Laboratories International Inc (CRL)'s business?

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

arrow icon

What is the price predicton of CRL Stock?

Wall Street analysts forecast CRL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRL is 192.73 USD with a low forecast of 165.00 USD and a high forecast of 225.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Charles River Laboratories International Inc (CRL)'s revenue for the last quarter?

Charles River Laboratories International Inc revenue for the last quarter amounts to 1.00B USD, decreased -0.49 % YoY.

arrow icon

What is Charles River Laboratories International Inc (CRL)'s earnings per share (EPS) for the last quarter?

Charles River Laboratories International Inc. EPS for the last quarter amounts to 1.10 USD, decreased -17.29 % YoY.

arrow icon

What changes have occurred in the market's expectations for Charles River Laboratories International Inc (CRL)'s fundamentals?

The market is revising Upward the revenue expectations for Charles River Laboratories International, Inc. (CRL) for FY2025, with the revenue forecasts being adjusted by 0.55% over the past three months. During the same period, the stock price has changed by 12.23%.
arrow icon

How many employees does Charles River Laboratories International Inc (CRL). have?

Charles River Laboratories International Inc (CRL) has 18600 emplpoyees as of December 05 2025.

arrow icon

What is Charles River Laboratories International Inc (CRL) market cap?

Today CRL has the market capitalization of 9.06B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free